摘要
目的研究分析KRAS及BRAF基因突变在原发性肝癌中的表达及临床意义,分析其与疾病发展相关性。方法选取2016年1月至2017年5月期间在我院接受诊治的126例肝癌患者作为研究对象,其中原发性肝癌且伴肝外转移者62例(研究组),病灶局限在肝脏者64例(对照组)。所有患者均于入院接受诊治当天空腹状态下抽取10ml外周血,由血样内游离DNA,应用KRAS/NRAS基因突变的联合检测试剂盒、人类BRAF基因V600E突变的检测试剂盒检测KRAS、BRAF基因突变,对基因突变率、突变临床特征进行分析。结果 126例患者中检出KRAS基因突变者15例,其中伴肝外转移的KRAS基因突变率是24.2%(15/62),但无肝外转移的突变率是0.0%(0/64);伴肝外转移患者的KRAS基因突变率显著高于无肝外转移患者的KRAS基因突变率,差异有统计学意义(P<0.05);提示KRAS基因突变和肝癌伴肝外转移存在显著相关性;126例患者中均无BRAF基因突变检出。结论肝癌患者的KRAS基因出现显著突变,同时肝癌伴肝外转移者的KRAS基因突变率显著增加;无BRAF基因突变检出,或BRAF基因突变率表现较低。
Objective To study the expression and clinical significance of KRAS and BRAF mutations in primary hepatocellular carcinoma(HCC),and analyze their relationship with disease development.Methods 126 cases of HCC patients treated in our hospital from January 2016 to May 2017 were enrolled in this study.Among them,62 cases of patients with primary HCC accompanied by extrahepatic metastasis(the study group),64 cases of patients with focal liver lesions(the control group).All patients were drawn on the day of admission for treatment of fasting 10ml peripheral blood samples from the blood free DNA,the application of KRAS/NRAS gene mutation detection kit,human BRAF gene V600E mutation detection kit KRAS,BRAF gene mutations,The gene mutation rate,mutation clinical features were analyzed.Results In 126 patients,KRAS mutation was found in 15 cases.The mutation rate of KRAS gene with extrahepatic metastasis was 24.2%(15/62),but the rate of non-extrahepatic metastasis was 0.0%(0/64).The mutation rate of KRAS gene in patients with extrahepatic metastasis was significantly higher than that in patients without extrahepatic metastasis,the difference was statistically significant(P<0.05).It is suggested that there is a significant correlation between KRAS gene mutation and extrahepatic metastasis of hepatocellular carcinoma.No mutation of BRAF gene was detected in 126 cases.Conclusion There was a significant mutation of KRAS gene in patients with hepatocellular carcinoma,and a significant increase of KRAS gene mutation rate in patients with hepatocellular carcinoma and extrahepatic metastasis.No mutation of BRAF gene was detected or the rate of BRAF gene mutation was lower.
作者
邬宇美
骆子义
黄华
WU Yu-mei;LUO Zi-yi;HUANG Hua(The Third People's Hospital of Shenzhen,Guangdong Shenzhen 518112,China)
出处
《新发传染病电子杂志》
2018年第1期37-40,共4页
Electronic Journal of Emerging Infectious Diseases
基金
深圳市科技计划项目(JCYJ20160427153326556)
